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INTRODUCTION
Infantile jaundice can arise through a variety of causes, 
with biliary atresia (BA) being one of them. BA leads to 
hepatic fibrosis without surgical correction, which may 
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progress to hepatic failure and eventually require liver 
transplantation (1, 2); hence, early diagnosis of BA is of 
paramount importance in infants presenting jaundice. 
Various imaging modalities, including ultrasonography 
(US) and MRI, are commonly used to diagnose BA (3, 
4). Associated findings include the triangular cord 
sign, invisible common bile duct, abnormal gallbladder 
morphology, enlarged hepatic artery, splenomegaly, 
increased liver stiffness through elastography, which can 
be seen both on US and MRI, and hepatic subcapsular 
flow (detected on Doppler US) (3-7). The combination of 
these imaging findings allows the diagnosis of BA before 
operation (3, 8). US is the most commonly used imaging 
technique; however, MRI is employed to differentiate the 
causes of hyperbilirubinemia because it is less affected by 
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the practitioner’s skills and provides a larger field of view 
with a good spatial resolution (9, 10).
Another strength of hepatobiliary MRI is diffusion-
weighted imaging (DWI), a type of quantitative imaging 
associated with hepatic fibrosis (11, 12). Many studies 
show that, in patients with chronic liver disease, as 
fibrosis progresses, hepatic apparent diffusion coefficient 
(ADC) values are lowered and can be used to evaluate liver 
fibrosis as similarly to other non-invasive methods of blood 
chemistry tests (13, 14). In previous studies, ADC values 
and clinical scores for assessing hepatic fibrosis showed 
a significant correlation in patients with BA (15, 16). 
However, only a few report the use of DWI in the diagnosis 
of BA and, in particular, on the relationship between the 
histologically diagnosed degree of hepatic fibrosis and DWI 
in pediatric patients (17). 
Therefore, the purpose of this study was to investigate 
whether the values of hepatic ADC of liver MRI would 
differentiate BA from non-BA and correlate with the grade 
of hepatic fibrosis in infants with cholestasis.
MATERIALS AND METHODS
Subjects
This retrospective cohort study was approved by our 
Institutional Review Board, and the need for informed 
consent was waived. However, written informed consent 
for sedation and MRI was received before each examination 
as routine clinical practice. Infants who underwent liver 
MRI examinations to evaluate hyperbilirubinemia from 
July 2009 to October 2017 were included. Liver MRI was 
performed in all consecutive infants suspected of various 
hepatobiliary diseases including BA or choledochal cyst, 
presenting persistent hyperbilirubinemia even after 
conservative treatment. We excluded patients when DWI was 
not included in the MRI scan or when patients were older 
than 12 months at the time of diagnosis. Included subjects 
were divided into BA and non-BA groups according to the 
intraoperative cholangiography findings and pathologic 
results, or clinical follow up. 
Demographic data assessed included age, sex, aspartate 
aminotransferase (AST, IU/L), alanine transaminase (ALT, 
IU/L), total bilirubin (mg/dL), direct bilirubin (mg/dL), 
alkaline phosphatase (ALP, IU/L), γ-glutamyl transferase 
(γGT, IU/L), and platelet count (103/μL) at the time of 
MRI examination. The AST to platelet ratio index (APRI), 
known as a clinical parameter of hepatic fibrosis (18), 
was calculated from the ratio of platelet count to AST. 
Additionally, histologic grades of hepatic fibrosis were 
obtained using the METAVIR grading system (F0 as no 
fibrosis, F1 as portal fibrosis without septal fibrosis, F2 as 
portal fibrosis with a few septal fibrosis, F3 as numerous 
septal fibrosis, and F4 as cirrhosis) if the patient underwent 
intraoperative or percutaneous liver biopsy within one-
month following liver MRI. 
MRI Acquisition
Liver MRI was performed using an 1.5T system (Intera 
Achieva; Philips Healthcare) with a cardiac coil. The MR 
examinations were performed under sedation offered by a 
trained pediatric sedation team, and the patients were in 
free-breathing status. The sequences of MRI included axial 
and coronal T2-weighted single-shot fast spin-echo, axial 
T1-weighted spin-echo, coronal respiratory-gated fast spin-
echo three-dimensional MR cholangiopancreatography, and 
axial DWI. A transverse fat-suppressed single-shot spin 
echo-planar imaging was performed using the following 
parameters: repetition time/echo time, 2000 ms/64.1 ms; 
matrix size, 128 x 128; field of view, up to 240 mm; slice 
thickness, 7 mm; number of excitation, 2.0; flip angle, 90°; 
b-values of 0, 500, 1000 s/mm2 or 0, 100, 150, 500, 1000 
s/mm2; and tridirectional diffusion gradients.
Image Analysis
Spleen size was measured on axial and coronal images 
and the larger value was determined as spleen size.
To obtain liver ADC values, circular regions-of-interest 
(ROIs) were drawn in the axial images of the right hepatic 
lobe avoiding the areas of respiratory motion, artifact, and 
major vessels (Fig. 1). Additional circular ROIs were also 
drawn at the central portion of the spleen avoiding gross 
vessels. The diameter of the ROI was about 12 mm on the 
liver and 8 mm on the spleen. These evaluations for ADC 
values were independently performed by two radiologists 
with 15 and 3 years of experience in liver MRI, respectively. 
The ADC value was calculated automatically from each ROI 
of DWI sequences using all available b-values from the 
mono-exponential fit. The ADC ratio of liver/spleen was also 
used for normalization (19, 20).
Statistical Analysis
Statistical analyses were performed using SPSS version 23 
(IBM Corp.) and MedCalc version 19.1.3 (MedCalc software). 
Inter-observer agreement was evaluated for the data of ADC 
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values from the two reviewers using intraclass correlation 
analysis. The absolute difference was also checked for ADC 
from the two reviewers. The subsequent analysis used the 
ADC values from the first reviewer. Demographic data and 
ADC values were compared between BA and non-BA groups 
using the independent t test and chi-square test. Kendall’s 
tau coefficient was used to evaluate the correlation between 
clinical parameters or ADC values and the histologic grade of 
hepatic fibrosis. The diagnostic performances for significant 
hepatic fibrosis (F3 and F4) were assessed and compared 
using the area under the receiver-operating characteristic 
curve (AUC) analysis. All data were presented as the mean 
and standard deviation. P values less than 0.05 were 
considered statistically significant.
RESULTS
Subjects and Baseline Characteristics
Altogether, 227 infants were included in the evaluation 
of cholestasis. Among them, 125 patients (55.1%, 44 
males and 81 females) were diagnosed to have BA with 
operative and pathologic confirmation and the other 102 
patients (44.9%, 54 males and 48 females) were assigned 
to the non-BA group, including diagnoses of choledochal 
cyst (n = 44), acute hepatitis (n = 18), genetic disorders 
(n = 9), metabolic disease (n = 5), paucity of intrahepatic 
bile duct (n = 2), biliary dyskinesia (n = 1), inspissated 
bile syndrome (n = 1), and idiopathic condition (n = 22). 
The clinical and laboratory results of the two groups 
are shown in Table 1. The age at the time of MRI was not 
significantly different between the two groups (p = 0.892), 
but the gender distribution was significantly different, with 
more female patients included in the BA group (p = 0.005). 
Among the laboratory results, AST, ALT, direct bilirubin, 
ALP, and γGT were significantly higher in the BA group 
compared with the non-BA group (Table 1). However, the 
APRI calculated from the ratio of platelets and AST was not 
different between the two groups (p = 0.149). 
Liver MRI Results
Spleen size, as measured on the liver MRI, was 
significantly larger in the BA group compared with the non-
BA group (mean, 6.2 ± 1.1 vs. 5.5 ± 1.1 cm; p < 0.001).
For ADC evaluation, 3 b-values were used in 211 patients 
including 113 from BA and 98 from non-BA groups. In 
addition, 5 b-values were used in 16 patients as 12 from BA 
and 4 from non-BA groups. The distribution of the group 
members according to the different b-value numbers were 
not different (p = 0.078).
The ADC values from liver and spleen could be obtained 
in all included patients without failure or error. The mean 
size of the circular ROIs was 105.1 ± 15.2 mm2 for the 
liver and 57.3 ± 15.7 mm2 for the spleen. The intraclass 
correlation coefficients from the two reviewers’ data were 
0.875 for liver ADC values and 0.779 for spleen ADC values. 
The absolute difference for ADC was 0.101 ± 0.094 x 10-3 
mm2/s for liver and 0.103 ± 0.115 x 10-3 mm2/s for spleen. 
Table 1 shows the ADC values of the BA and non-BA groups, 
including liver ADC, spleen ADC, and the ratio of liver to 
spleen ADC. Liver ADC values (mean, 1.098 vs. 1.171 x 10-3 
Fig. 1. A representative case for measurement of imaging parameters from a 43-day-old girl diagnosed as biliary atresia.
A. The spleen size was measured as the largest diameter among measurements on axial and coronal views as shown in this case of axial T2-
weighted image. The spleen size was 6.0 cm. B. Circular regions-of-interest are drawn in the homogeneous parenchyma of liver and spleen 
avoiding major vessels on an axial image of ADC map. The ADC value was 0.975 x 10-3 mm2/s from liver and 0.932 x 10-3 mm2/s from spleen.  





mm2/s; p = 0.011) and the ratio of liver and spleen ADC 
values (mean, 1.26 vs. 1.33; p = 0.029) were significantly 
lower in the BA group than in the non-BA group. However, 
spleen ADC values were not different between the two 
groups (p = 0.338). 
Diagnosis of BA
Table 2 demonstrates the diagnostic performance to 
differentiate BA using the parameters from laboratory 
findings and MRI values. Among the laboratory parameters, 
γGT had the AUC value of 0.847 (p < 0.001), 87.2% 
sensitivity, and 71.7% specificity using the cutoff value of 
183 IU/L. APRI had 80.0% sensitivity and 52.9% specificity 
for the diagnosis of BA with a cutoff value of 0.455 (AUC 
value of 0.669, p < 0.001). Among the MRI parameters, 
spleen size had 72.8% sensitivity and 61.8% specificity 
for the diagnosis of BA with a cutoff value of 5.6 cm (AUC 
value of 0.690, p < 0.001). The liver ADC showed the 
highest specificity of 80.4% for the diagnosis of BA when 
using the cutoff value of 1.044 x 10-3 mm2/s (AUC value 
of 0.620, p = 0.001). The ADC ratio of liver and spleen 
showed the highest sensitivity of 88.0% among the imaging 
parameters with the cutoff value of 1.4.
The combined parameter of γGT and spleen size had an 
AUC value of 0.861 (p < 0.001) and the combined parameter 
of γGT, spleen size, and liver ADC had AUC value of 0.862 
(p < 0.001) without significant differences. The AUC values 
of only γGT and the combined parameter of γGT, spleen size, 
Table 1. Comparison of Clinical and Laboratory Results and 








Age (days) 56.9 ± 30.2 57.6 ± 42.8 0.892
Sex (male:female) 44:81 54:48 0.005
Laboratory results
AST (IU/L) 181.3 ± 160.3 121.5 ± 142.7 0.004
ALT (IU/L) 122.9 ± 112.3 85.0 ± 124.4 0.017
Total bilirubin 
  (mg/dL)
7.6 ± 2.8 6.7 ± 4.4 0.076
Direct bilirubin 
  (mg/dL)
5.8 ± 2.3 3.8 ± 3.3 < 0.001
ALP (IU/L) 473.5 ± 207.9 406.2 ± 276.5 0.038
γGT (IU/L) 466.2 ± 338.7 175.7 ± 201.4 < 0.001
Platelet (103/μL) 439.6 ± 151.4 427.9 ± 155.6 0.567
APRI 1.5 ± 1.6 1.1 ± 1.9 0.149
Imaging findings
Spleen size (cm) 6.2 ± 1.1 5.5 ± 1.1 < 0.001
Liver ADC 
  (x 10-3 mm2/s)
1.098 ± 0.211 1.171 ± 0.220 0.011
Spleen ADC 
  (x 10-3 mm2/s)
0.880 ± 0.166 0.903 ± 0.206 0.338
Liver/spleen ADC 1.26 ± 0.19 1.33 ± 0.25 0.029
P values from independent t test except for sex from chi-
square test. ADC = apparent diffusion coefficient, ALP = alkaline 
phosphatase, ALT = alanine transaminase, APRI = aspartate 
aminotransferase to platelet ratio index, AST = aspartate 
aminotransferase, BA = biliary atresia, γGT = γ-glutamyl transferase
Table 2. Diagnostic Performance of Laboratory and Imaging Parameters for the Differentiation of BA
Parameters AUC (95% Confidence Interval) P Cutoff Values Sensitivity (%) Specificity (%)
Laboratory results
AST (IU/L) 0.698 (0.634–0.757) < 0.001 > 70 82.4 57.8
ALT (IU/L) 0.693 (0.628–0.752) < 0.001 > 31 90.4 49.0
Direct bilirubin (mg/dL) 0.710 (0.646–0.768) < 0.001 > 3.2 89.6 48.5
ALP (IU/L) 0.619 (0.552–0.682) 0.002 > 301 82.4 45.1
γGT (IU/L) 0.847 (0.793–0.892) < 0.001 > 183 87.2 71.7
APRI 0.669 (0.604–0.730) < 0.001 > 0.455 80.0 52.9
Imaging findings
Spleen size (cm) 0.690 (0.626–0.750) < 0.001 > 5.6 72.8 61.8
Liver ADC (x 10-3 mm2/s) 0.620 (0.553–0.683) 0.001 ≤ 1.044 45.6 80.4
Liver/spleen ADC 0.589 (0.522–0.654) 0.019 ≤ 1.4 88.0 27.5
Combined parameters
γGT + spleen size 0.861 (0.812–0.910) < 0.001
γGT + liver ADC 0.852 (0.800–0.904) < 0.001
Spleen size + liver ADC 0.691 (0.622–0.761) < 0.001
γGT + spleen size + liver ADC 0.862 (0.813–0.911) < 0.001
AUC = area under the receiver-operating characteristic curve
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and liver ADC were not different (p = 0.429). 
Correlation between Histologic Grades of Hepatic 
Fibrosis and Parameters
The mean time interval between MRI examination and 
histologic evaluation was 4.5 ± 4.3 days (range, 0–27 
days). Histologic grades of hepatic fibrosis according to 
the METAVIR grading system were obtained for 165 patients 
through intraoperative or percutaneous biopsy. There 
were 33 patients with F0 (BA:non-BA = 2:31), 15 with F1 
(BA:non-BA = 8:7), 71 with F2 (BA:non-BA = 65:6), 35 with 
F3 (BA:non-BA = 34:1), and 11 with F4 (BA:non-BA = 11:0). 
The ADC values from the liver and spleen and the grades 
of hepatic fibrosis were not different between the groups 
using 3 b-values and 5 b-values (all, p > 0.05). 
The correlations of fibrosis grades and the parameters 
are shown in Figure 2. There were significant correlations 
between hepatic fibrosis grades and all four parameters 
of APRI (τ = 0.296), spleen size (τ = 0.312), liver ADC 
(τ = -0.206), and ADC ratio (τ = -0.288) (all, p < 0.001). 
However, the spleen ADC value was not correlated with 
hepatic fibrosis grade (τ = 0.035, p = 0.550). Among the 
clinical and laboratory parameters, age (τ = 0.279) and γGT 
(τ = 0.352) also showed correlation with fibrosis grades 
(both, p < 0.001). 
On the partial correlation analysis considering the BA 
group, age (τ = 0.383, p < 0.001), γGT (τ = 0.242, p = 
0.002), spleen size (τ = 0.248, p = 0.001), liver ADC (τ = 
-0.224, p = 0.004), and ADC ratio (τ = -0.291, p < 0.001) 
also showed correlation with hepatic fibrosis grades. 
However, APRI (τ = 0.094, p = 0.232) and spleen ADC (τ = 
0.026, p = 0.746) were not correlated with hepatic fibrosis 
grades. 
Assessment and Comparison of Diagnostic Performances 
for Significant Hepatic Fibrosis
The diagnostic performances of the parameters for 
significant hepatic fibrosis (F3–4), including APRI, spleen 
Fig. 2. Box plots for comparison of hepatic fibrosis grades and parameters. 
Box plots show the values according to the hepatic fibrosis grade of APRI (A), spleen size (B), liver ADC (C), and the ADC ratio of liver and spleen 
(D). The values of APRI (τ = 0.296) and spleen size (τ = 0.312) showed positive correlation and the values of liver ADC (τ = -0.206) and ADC ratio  




















































































size, liver ADC, and ADC ratio are shown in Table 3 and 
Figure 3. The AUC value of APRI was 0.721, and the 
suggested cutoff value was 0.783. Spleen size of more than 
5.9 cm showed 84.8% sensitivity and 56.3% specificity, 
and the AUC was 0.719. The liver ADC value ≤ 1.044 x 10-3 
mm2/s showed an AUC value of 0.673 (95% confidence 
interval [CI], 0.596–0.744), and the ADC ratio value ≤ 1.22 
showed an AUC value of 0.651 (95% CI, 0.573–0.723). 
When the AUC of these four parameters were compared, 
none showed any significant difference for diagnosing 
significant hepatic fibrosis (all, p > 0.2).
When considering the BA group only (120 patients), 
the AUC value of age was 0.787 with 93.3% sensitivity 
and 53.3% specificity when using the cutoff value of 45 
days for diagnosing significant hepatic fibrosis. When the 
parameters of age, APRI, spleen size, and liver ADC values 
were combined, as shown in Table 3, the highest AUC value 
was 0.796 (95% CI, 0.715–0.878) in combination of age, 
spleen size and liver ADC value. However, the AUC values 
were not statistically different.
DISCUSSION
It is important to differentiate BA from non-BA in 
neonatal cholestasis; it is also desirable to evaluate 
hepatic fibrosis grades non-invasively in these patients. 
Our study showed that spleen size measured on MRI, liver 
ADC value, and ADC ratio of liver/spleen could differentiate 
BA from non-BA patients. Liver ADC value was a specific 
(80.4%) and ADC ratio a sensitive (88.0%) parameter for 
Table 3. Diagnostic Performances of Laboratory and Imaging Parameters for the Differentiation of Significant Fibrosis (F3–4)
Parameters AUC (95% Confidence Interval) P Cutoff Values Sensitivity (%) Specificity (%)
All patients
Laboratory results
AST (IU/L) 0.755 (0.682–0.818) < 0.001 > 146 73.9 72.3
ALT (IU/L) 0.761 (0.688–0.823) < 0.001 > 74 80.4 66.4
Direct bilirubin (mg/dL) 0.732 (0.657–0.798) < 0.001 > 5.3 78.3 63.9
ALP (IU/L) 0.668 (0.590–0.739) < 0.001 > 298 95.7 33.6
γGT (IU/L) 0.708 (0.632–0.776) < 0.001 > 382 67.4 71.4
APRI 0.721 (0.646–0.788) < 0.001 > 0.783 80.4 60.5
Imaging findings
Spleen size (cm) 0.719 (0.644–0.786) < 0.001 > 5.9 84.8 56.3
Liver ADC (x 10-3 mm2/s) 0.673 (0.596–0.744) < 0.001 ≤ 1.044 63.0 68.1
Liver/spleen ADC 0.651 (0.573–0.723) 0.001 ≤ 1.22 58.7 64.7
Only BA group
Combined parameters
Age (days) 0.787 (0.703–0.856) < 0.001 > 45 93.3 53.3
Age + APRI 0.790 (0.706–0.874) < 0.001
Age + spleen size 0.790 (0.706–0.875) < 0.001
APRI + spleen size 0.721 (0.629–0.813) < 0.001
Age + APRI + spleen size 0.795 (0.711–0.879) < 0.001





















Fig. 3. Receiver-operating characteristics curves of the 
parameters including APRI, spleen size, liver ADC, and ADC 
ratio of liver and spleen for the diagnosis of significant hepatic 
fibrosis (F3–4). No significant differences were observed between the 
parameters (all, p > 0.2).
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the diagnosis of BA. Moreover, these parameters could be 
used to predict the histologic degree of hepatic fibrosis. 
Splenomegaly more than 5.9 cm, hepatic ADC values lower 
than 1.044 x 10-3 mm2/s and ADC ratio lower than 1.22 
were associated with significant hepatic fibrosis (F3–4), 
even though the diagnostic performance was not superior 
to APRI.
Our study also demonstrated good inter-observer 
agreement for the measurement of ADC in infantile liver MRI 
with free breathing. The intraclass correlation coefficients 
were 0.875 for the liver and 0.779 for the spleen. Moreover, 
the ADC ratio of the liver and spleen showed the same trend 
as the liver ADC value. There was no study using normalized 
ADC value taking the spleen as the reference organ, which 
could decrease variability in ADC measurement (20).
Previously, only a few studies suggested the utility of 
DWI parameters for diagnosing BA. Two studies reported 
lower hepatic ADC values in BA patients compared with 
the values in control subjects (15, 16). However, the 
number of BA patients was small (n = 32 or 33), and the 
age range was wide (0–13 years). Moreover, they showed 
the difference between BA patients and normal healthy 
subjects, but not with non-BA cholestasis patients. A recent 
study in 59 neonates and infants demonstrated the utility 
of diffusion tensor imaging in neonatal cholestasis for the 
differentiation of BA from non-BA (17). When using the 
b-values of 0 and 1000 s/mm2, the ADC cutoff value of 1.317 
x 10-3 mm2/s showed 78% sensitivity and 81.5% specificity 
for diagnosing BA (17). However, there was no difference 
in fractional anisotropy values between the two groups. 
Although the study is meaningful, the number of included 
patients was still small. Our study included several times 
the number of patients in existing studies, all of which 
were neonates and infants with cholestasis. Our results 
were consistent with previous studies showing significantly 
lower ADC values in the BA group compared with the non-
BA group. The suggested cutoff value of our study was  
1.044 × 10-3 mm2/s, which is lower than that of the previous 
report. This may be due to the use of different b-values and 
different levels of fibrosis in the patient population.
Not only conventional DWI with the mono-exponential 
model, but also advanced DWI techniques with bi- or 
stretched-exponential models can be used nowadays. In 
our study, we used both 3 and 5 b-values including the 
b-value of 0 s/mm2, which can theoretically introduce 
perfusion effects into the diffusion data. In a previous 
study, there was no significant difference between diffusion 
parameters using mono-, bi-, and stretched-exponential 
models in differentiating BA from non-BA in infants with 
hyperbilirubinemia, even using only two b-values (21). 
Similarly, another study found that ADC derived from the 
mono-exponential model was the most valuable parameter 
among a variety of analytical methods including mono-, bi-, 
and stretched-exponential, and kurtosis models in renal cell 
carcinoma subtype analysis (22). Thus, ADC derived from 
the mono-exponential model, even with small b-values, 
could not be inferior to other novel DWI analytical models. 
Moreover, in pediatric patients, the use of multiple b-values 
leads to longer anesthesia, so if a small b-value number can 
achieve similar performance, the analysis using a mono-
exponential model with fewer b-values is also meaningful.
Several studies have shown a correlation between hepatic 
fibrosis grades and hepatic ADC values in adults using 
variable DWI analysis (13, 23, 24). However, only three 
studies dealt with the correlation between the two in 
pediatric patients. The first study reported that the right 
liver ADC value showed a negative correlation with liver 
scores in 33 BA patients and 18 healthy subjects without 
pathologic evaluation (15). The second report showed 
that the right liver to psoas ADC ratios in 32 BA patients 
were negatively correlated with clinical or histological 
hepatic fibrosis grades (16). However, most patients were 
F4 (19/32, 59%) and no patients were F0 or F1. In the 
other study using diffusion tensor imaging for evaluating 
hepatic fibrosis grades of BA patients, the ADC value could 
not differentiate fibrosis grades (17). None of the studies 
compared the diagnostic performance of hepatic ADC value 
with APRI or spleen size. 
The patients of our study were distributed relatively 
evenly among each fibrosis group, and this study showed 
that the degree of hepatic fibrosis in neonatal cholestasis 
and the diagnosis of BA were associated with liver 
ADC values. In addition, we compared the diagnostic 
performance of APRI and spleen size in determining 
significant fibrosis, which showed no significant difference 
from that of liver ADC values. Overall analysis in this large 
cohort study confirmed that diffusion parameters have the 
possibility of non-invasively monitoring hepatic fibrosis 
and of overcoming sampling error, which is a limitation of 
conventional biopsy.
In general, BA patients receive the Kasai operation first, 
but a large number of them develop end-stage liver disease 
resulting in liver transplantation (25, 26). Hepatic fibrosis is 




with severe fibrosis had a worse overall survival of the liver 
regardless of age at the time of the Kasai operation (2). In 
addition, a higher incidence of bowel perforation or biliary 
complications after liver transplantation has been reported 
in patients who have undergone prior Kasai operations 
(27, 28). A recent meta-analysis demonstrated that a 
portoenterostomy prior to liver transplantation had a higher 
risk of postoperative infection (29). Therefore, immediate 
liver transplantation instead of the Kasai operation as the 
bridge could lead to better prognosis in some selected 
patients (30, 31). Diagnosis of the hepatic fibrosis grade 
through imaging procedures, as performed in this study, 
can be helpful in predicting prognosis in BA patients and 
ultimately in determining the treatment plan, even though 
age was also a significant predictor. Further research is 
needed on the prognostic value of hepatic fibrosis grading 
through imaging studies.
Even though γGT alone showed high diagnostic 
performance for BA in our study, we cannot use this 
parameter alone in real-world situations. One of the most 
common causes of neonatal cholestasis is BA, but it 
accounts for about 25–40% (32). γGT value is generally 
elevated in neonatal cholestasis, not only in BA but also 
in Alagille syndrome, progressive familial intrahepatic 
cholestasis type 3, choledochal cyst with cholangitis, and 
some cases of alpha-1-antitrypsin deficiency. The primary 
test for diagnosing neonatal cholestasis is a laboratory 
test, which detects an increase in γGT following the 
identification of gross structural abnormalities by US. 
However, if structural abnormalities are not clear, liver 
biopsy or genetic study is recommended, rather than liver 
MRI. Although γGT appears to have a high diagnostic 
performance for BA in this study, as this study only 
included patients who underwent liver MRI in consideration 
of structural abnormalities, this will show different results 
if we applied it in general infantile jaundice patients.
There are several limitations to this study. Our study is a 
retrospective study only including patients with liver MRI, 
even though we considered all consecutive studies. We 
included patients not only with conjugated but also non-
conjugated hyperbilirubinemia who underwent liver MRI. 
As liver MRI is not recommended for infants with hepatitis, 
who improve through conservative treatment or without 
any structural lesions on US at the initial evaluation, there 
could be selection bias. The second limitation is that 
we included both ADC values from 3 or 5 b-values, even 
though we demonstrated no remarkable difference in results 
between these two groups. There is also a measurement 
error problem for ADC, even though we demonstrated inter-
observer variability and absolute inter-observer difference. 
Additional studies including intra-observer variability 
are needed. The third limitation is the lack of evaluation 
for additional effects on conventional US or MR based 
diagnoses. In clinical practice, the diagnosis is made 
through a combination of multiple findings, rather than just 
one imaging finding. We do not differentiate BA from the 
choledochal cyst based on DWI finding. However, the high 
specificity of liver ADC value for diagnosing BA could be one 
of the helpful findings. Therefore, for practical evaluation, it 
would be better to assess the diagnostic ability of diffusion 
parameters in addition to existing findings. In addition, 
the role of DWI can be interpreted as helping to predict 
the degree of hepatic fibrosis when the diagnosis is already 
possible by other findings. 
In conclusion, liver ADC and ADC ratio of liver/spleen 
were significantly lower in BA patients compared with non-
BA patients. All analyzed parameters, including APRI, spleen 
size, hepatic ADC, and the ratio of liver and spleen ADC 
values, showed a significant correlation with the histologic 
hepatic fibrosis grade, in spite of considerable overlaps. 
Especially, AUC values of the parameters ranged between 
0.651–0.721 for diagnosing significant hepatic fibrosis (F3–
F4). Thus, hepatic diffusion parameters may have limited 
diagnostic performance to differentiate BA from the non-
BA and predict the histologic degree of hepatic fibrosis in 
neonatal cholestasis patients. The inter-observer variability 
should be considered and further study for the additional 
evaluation of these parameters is needed. 
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